You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News items for the week of Feb. 3, 2020.
The deal follows a number of recent acquisitions in the animal genomics space for Neogen including Canadian animal genomics firm Delta Genomics Centre.
Neogen this week announced that its NeoSeek genetic test for Shiga toxin-producing strains of Escherichia coli (STEC) has received validation from AOAC.
Edmonton-based Delta Genomics Centre becomes Neogen's fifth animal genomics laboratory, joining ones in Australia, Brazil, Scotland, and the US.
The lab is a major genetic testing supplier to all 27 of Australia's major beef cattle associations, and provides services for other farm animals.
The transaction is expected to boost Neogen's presence in Brazil, allowing it to leverage Deoxi's relationships with customers in that country.
The test is based on isothermal amplification and detects L. monocytogenes in about 10 minutes after sample processing.
Under the agreement, customers will be able to purchase GeneSeek Genomic Profiler SNP arrays from Illumina, initially for genotyping cattle, pigs, and horses.
Illumina has become the dominant player in the cattle genotyping field, while array vendors are beginning to envision a future where every animal is genotyped at birth.
NEW YORK (GenomeWeb) – Merck Animal Health will market Neogen's genomic tests for assessing the genetic potential of replacement dairy heifers under an agreement announced today.
Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.